Basilea Pharmaceutica Ownership
| BPMUF Stock | USD 52.83 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Basilea |
Basilea Pink Sheet Ownership Analysis
About 29.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 200.0. Basilea Pharmaceutica had not issued any dividends in recent years. Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States.The quote for Basilea Pharmaceutica AG is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Basilea Pharmaceutica AG please contact the company at 41 61 606 11 11 or go to https://www.basilea.com.Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.